Precertification requirements for Part B drugs

Amerigroup STAR+PLUS Medicare-Medicaid Plan is adding the following new drugs to the 2015 list of Part B injectable and infusible drugs requiring prior authorization. As of October 1, 2015, providers must call for prior authorization of these drugs:

1. Entyvio (vedolizumab): a monoclonal antibody that is a specific integrin receptor antagonist used for the treatment of moderate to severe active Crohn’s disease and ulcerative colitis in adult patients. (C9026)
2. Cyramza (ramucirumab): a monoclonal antibody and human vascular endothelial growth factor receptor 2 antagonist used for treatment of metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression during or after treatment with fluoropyrimidine- or platinum-containing chemotherapy. (C9025)

Noncompliance with these new requirements may result in denied claims.

For more information

If you have questions or would like more information about the topics discussed in this bulletin, please call us or visit our website:

Phone: 1-855-878-1785
Website: providers.amerigroup.com/TX